Evenamide, as an add-on to antipsychotics, produces long-lasting clinically meaningful benefit and converts treatment-resistant schizophrenia (TRS) patients into a responsive state: 6-month results from an ongoing international randomized study

[P502] Evenamide, as an add-on to antipsychotics, produces long-lasting clinically meaningful benefit and converts treatment-resistant schizophrenia (TRS) patients into a responsive state: 6-month results from an ongoing international randomized study

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Francesca Sansi², Rodolfo Giuliani² (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA)

キーワード：Treatment resistant schizophrenia, long-term treatment, glutamate modulation, add-on treatment, pharmacological intervention

抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。